Fluprednisolone

Summary

Fluprednisolone (CHEMBL1200774) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 378.4 Da · C21H27FO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200774
Name	Fluprednisolone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5876
Molecular formula	C21H27FO5
Molecular weight	378.4
InChIKey	MYYIMZRZXIQBGI-HVIRSNARSA-N

SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)C[C@@H](C4=CC(=O)C=C[C@]34C)F)O

IUPAC name: (6S,8S,9S,10R,11S,13S,14S,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one

Also known as: Alphadrol, Fluprednisolona, Fluprednisolone, NSC-47439, U-7800, FLUPREDNISOLONE, SID144205251, SID144206694, SID170465086

Patent coverage: 2,527 distinct patent families (9,761 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).